Overview

To Evaluate the Food Effect on Pharmacokinetic Profiles and Safety in Healthy Volunteers

Status:
NOT_YET_RECRUITING
Trial end date:
2024-08-08
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, single dose, crossover, phase 1 trial to evaluate the food effect on pharmacokinetic profiles and safety of CKD-383 in healthy volunteers
Phase:
PHASE1
Details
Lead Sponsor:
Chong Kun Dang Pharmaceutical
Treatments:
empagliflozin
lobeglitazone
Metformin